People with persistent acid reflux and several risk factors for oesophageal cancer could be offered a seven-minute capsule sponge test instead of an initial endoscopy under draft guidance published by the National Institute for Health and Care Excellence (NICE) on 16 November 2026. But the test is not a universal substitute: people with abnormal results may still need an endoscopy, which allows doctors to examine the oesophagus and take tissue samples.
The draft guidance recommends two capsule sponge technologies, Cytosponge and EndoSign, for people with persistent gastro-oesophageal reflux disease (GORD), commonly known as acid reflux, and multiple risk factors for oesophageal cancer.